TransMedics Group (NASDAQ:TMDX) Price Target Lowered to $109.00 at Needham & Company LLC

TransMedics Group (NASDAQ:TMDX) had its price objective decreased by Needham & Company LLC from $208.00 to $109.00 in a research report released on Tuesday morning, Marketbeat Ratings reports. Needham & Company LLC currently has a buy rating on the stock.

Other equities analysts have also issued reports about the company. Canaccord Genuity Group upped their target price on TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Morgan Stanley upped their target price on TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Stephens boosted their price objective on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Piper Sandler reissued an “overweight” rating and issued a $180.00 price objective on shares of TransMedics Group in a report on Monday, October 7th. Finally, Oppenheimer increased their price objective on TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $144.80.

TransMedics Group Trading Up 0.5 %

Shares of TMDX opened at $82.40 on Tuesday. The stock’s 50-day moving average is $140.51 and its two-hundred day moving average is $139.29. The stock has a market cap of $2.77 billion, a PE ratio of 87.66 and a beta of 1.99. TransMedics Group has a 12 month low of $38.13 and a 12 month high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 8.48.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the previous year, the firm posted ($0.12) earnings per share. The firm’s revenue was up 63.7% compared to the same quarter last year. Equities analysts forecast that TransMedics Group will post 1.11 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $8,180,642.53. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the sale, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,180,642.53. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $149.96, for a total transaction of $1,012,230.00. Following the sale, the director now owns 732 shares of the company’s stock, valued at $109,770.72. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 61,247 shares of company stock valued at $9,518,181 in the last three months. 7.00% of the stock is owned by corporate insiders.

Institutional Trading of TransMedics Group

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in TransMedics Group by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock valued at $147,214,000 after purchasing an additional 50,673 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in TransMedics Group by 5.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock valued at $94,061,000 after purchasing an additional 30,092 shares during the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in TransMedics Group in the 2nd quarter valued at about $1,400,000. Handelsbanken Fonder AB lifted its stake in TransMedics Group by 657.6% in the 3rd quarter. Handelsbanken Fonder AB now owns 64,400 shares of the company’s stock valued at $10,111,000 after purchasing an additional 55,900 shares during the last quarter. Finally, State of Alaska Department of Revenue acquired a new stake in TransMedics Group in the 3rd quarter valued at about $2,560,000. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.